نتایج جستجو برای: drug industry
تعداد نتایج: 773051 فیلتر نتایج به سال:
After the thalidomide tragedy governments in Europe and North America established new requirements for drug testing intended to protect the public from ineffective and unsafe drugs. As no drugs are entirely safe, regulators must determine whether manufacturers have provided enough evidence to show that drugs’ benefits outweigh their harms. Precisely how high the evidence bar should be set for m...
Correspondence to Dr Wolfgang Wein; wolfgang. [email protected] ISSUE 1: DEMOGRAPHICS Currently, the world population is heading for an 11 billion people peak in the next decades. Owing to the successful and victorious efforts and strategies of the academia, pharmaceutical industry and regulators, the average life expectancy of the European population will be close to a hundred years by the m...
The re-focusing of pharmaceutical industry research away from early discovery activities is stimulating the development of novel models of drug discovery, notably involving academia as a 'front end'. In this article the authors explore the drivers of change, the role of new entrants (universities with specialised core facilities) and novel partnership models. If they are to be sustainable and d...
September 2005 | Volume 2 | Issue 9 | e241 Britain’s House of Commons Health Committee has recently recommended a fundamental realignment of the relationships between the pharmaceutical industry and government, regulators, doctors, the health service, and patients [1]. The committee said that the industry has interdigitated itself into every aspect of health care, and that government and others...
Different forms of protection for inventions in the pharmaceutical industry point to strategies for the perpetuation of patent protection. Based on a literature review showing the specificities of patenting in the industry, the article provides a brief history of drug patents in Brazil, a discussion of patentable and non-patentable inventions, and the modalities and traits of patent protection ...
A new report is calling for changes in the conduct of clinical trials in the United States to reduce disparities of age, sex, race, and comorbidity. The goal is to give a more representative picture of the benefits and risks of a treatment across the entire population but particularly among those who bear the greatest burden of the morbidity. The eliminating disparities in clinical trials (EDIC...
Diane Hardy, Chief Microbiologist, Regeneron Brian L. Bell, Senior Scientist, Bristol-Myers Squibb Ren-Yo Forng, Site Microbiologist, Astra Zeneca Michael Knight, Senior Manager QC Microbiology, Genentech Anita Bawa, Director QC, Bayer Stephanie Ramsey, Manager Quality Systems, Baxter Christine Arbesser-Rastburg, Director Quality Operations / Microbiology, Baxter Mousumi Paul, Associate Directo...
Essential to the renewal of interest in polarography and voltammetry in the 1970s were the availability of reliable polarographs offering the pulse mode, with sensitivity down to lo-‘-lo-* M and h’gh 1 er resolving power; a better understanding of the electrode processes of compounds of pharmaceutical interest (active agents, excipients, additives, antioxidants, etc.); and the application of ox...
Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید